The neutrophil to lymphocyte ratio is an independent predictor for severe COVID-19 : Evidence from a multicenter case-control study and meta-analyses

Wien Klin Wochenschr. 2021 Sep;133(17-18):882-891. doi: 10.1007/s00508-021-01917-9. Epub 2021 Aug 3.

Abstract

Purpose: The aim of this study was to determine whether the neutrophil to lymphocyte ratio (NLR) can predict severe Coronavirus disease 2019 (COVID-19).

Patients and methods: A multicenter case-control study was conducted to investigate whether the NLR can help predict the severity of COVID-19. Patients confirmed to have COVID-19 between 16 January 2020 and 15 March 2020 were enrolled. Furthermore, meta-analyses were conducted based on both previous studies and our case-control study.

Results: In the case-control study, 213 patients (severe: 81) were included. The results suggested that the NLR was an independent risk factor (odds ratio [OR], 1.155, 95% confidence interval [95% CI]: 1.043-1.279, P = 0.006) and a great predictor (the area under the ROC curve was 0.728, 95% CI: 0.656-0.800) for severe COVID-19. In total, 18 datasets from 16 studies combined with our case-control study (severe: 1211; non-severe: 5838) were included in the meta-analyses and the results showed that the NLR of the severe COVID-19 group was significantly higher than that of the non-severe group (SMD = 1.10, 95% CI: 0.90-1.31, P < 0.001). Based on the 2 × 2 data from 6 studies, the SROC of NLR for predicting severe COVID-19 was 0.802, with a sensitivity of 0.67 (95% CI: 0.61-0.72) and a specificity of 0.75 (95% CI: 0.73-0.78).

Conclusion: Based on a multicenter case-control study and a meta-analysis, we found that the initial NLR was a great predictor of severe COVID-19.

Keywords: Coronavirus disease 2019; Lymphocyte; Neutrophil; Risk factor; Severity.

Publication types

  • Meta-Analysis
  • Multicenter Study

MeSH terms

  • COVID-19*
  • Case-Control Studies
  • Humans
  • Lymphocyte Count
  • Lymphocytes
  • Multicenter Studies as Topic
  • Neutrophils*
  • Prognosis
  • Retrospective Studies
  • SARS-CoV-2